Website:
Location:
| Round | Amount raised ($M) | Date closed | Lead investors | Other new investors | Existing investors |
|---|
* Includes fundings from Jan 2018 through March 2021
| Product name | Modality | Target | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | FDA submission | Commercial |
|---|
| Assignees | Assignors | Title | Identifiers | Key dates | Inventors |
|---|
| NCT ID | Title | Summary | Phase | Condition | Design | Start date | Primary completion date | Completion date | Enrollment | Arms | Primary outcome | Secondary outcomes |
|---|
| Molecule name | Therapeutic modality | Target | Action type | Mechanism of action | Brand names | Companies | Number of clinical trials | Indications of clinical trials | Stages of clinical trials |
|---|
| Company name | Ticker | Series A date | Series A amount raised | Series A post-money | Series B date | Series B amount raised | Series B post-money | Series C date | Series C amount raised | Series C post-money | IPO date | IPO amount raised | IPO post-money | Therapeutic areas | Therapeutic modalities | Stage |
|---|
| Company name | Acquiror name | Deal date | Upfront value ($M) | Total value ($M) | Therapeutic areas | Development stage |
|---|
| Company name | Date | Round | Amount invested | Therapeutic areas | Stage | Location | Lead investors | New non-lead investors | Existing investors |
|---|